\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[T2A]{fontenc}
\usepackage[ngerman,polish,english]{babel}



\usepackage{float}








\begin{document}

\title{Path towards efficient paediatric formulation development based on
partnering with clinical pharmacologists and clinicians, a c4c expert
group White paper.}



\author[1]{Jennifer Walsh}%
\author[2]{Daniel Schaufelberger}%
\author[3]{Sonia Lurian}%
\author[4]{Sandra Klein}%
\author[5]{Hannah Batchelor}%
\author[6]{Roy Turner}%
\author[7]{Sveinbjörn Gizurarson}%
\author[8]{Luigi  Boltri}%
\author[9]{Elisa Alessandrini}%
\author[10]{Catherine Tuleu}%
\affil[1]{Jenny Walsh Consulting Ltd}%
\affil[2]{2.	Schaufelberger Consulting LLC}%
\affil[3]{Iuliu Haţieganu University of Medicine and Pharmacy}%
\affil[4]{Ernst-Moritz-Arndt Universitat Greifswald Mathematisch-Naturwissenschaftliche Fakultat}%
\affil[5]{University of Strathclyde}%
\affil[6]{Idorsia Pharmaceuticals Ltd}%
\affil[7]{University of Iceland}%
\affil[8]{Adare Pharmaceuticals}%
\affil[9]{UCL School of Pharmacy}%
\affil[10]{University College London School of Pharmacy}%


\vspace{-1em}



  
  \date{May 18, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
Improved global access to novel age-appropriate formulations for
paediatric subsets, either of new chemical entities or existing drugs,
is a priority to ensure that medicines meet the needs of these patients.
However, despite regulatory incentives, the introduction to the market
of paediatric formulations still lags behind adult products. This is
mainly caused by additional complexities associated with the development
of acceptable age-appropriate paediatric medicines. This position paper
proposes the use of a paediatric Quality Target Product Profile (pQTPP)
as an efficient tool to facilitate early planning and decision making
during the children-centric formulation design for new chemical
entities, or to repurpose/reformulate off-patent drugs. Essential key
attributes of a paediatric formulation are suggested and described.
Moreover, greater collaboration between formulation experts and clinical
colleagues, including healthcare professionals, is advocated to lead to
safe and effective, age-appropriate medicinal products. Acceptability
testing should be a secondary endpoint in paediatric clinical trials to
ensure post-marketing adherence is not compromised by a lack of
acceptability. Not knowing the indications and the related age groups
and potential dosing regimens early enough is still a major hurdle for
efficient paediatric formulation development; however the proposed pQTPP
could be a valuable collaborative tool for planning and decision making
to expedite paediatric product development.%
\end{abstract}%



\sloppy




\selectlanguage{english}
\FloatBarrier
\end{document}

